Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05648110 · ClinicalTrials.gov registry record · Phase 2
Parent Study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA Sub-study)
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 3,882
- Enrollment target
NCT05648110: Completed Phase 2 study, sponsored by AstraZeneca.
NCT05648110 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 3,882 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (2819% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05648110, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3,882 participants
- Enrollment target
Study Summary
AZD3152, a single mAb, is being developed to have broad neutralizing activity across known SARS-CoV-2 variants of concern for pre-exposure prophylaxis of COVID-19. The aim of the Phase I/III study (Parent Study) will be to evaluate the safety, efficacy and neutralizing activity of AZD3152 compared with comparator for pre exposure prophylaxis of COVID-19, and separately evaluate the safety and PK of AZD5156, a combination of AZD3152 and AZD1061. Sub-study: This Phase II sub-study of SUPERNOVA will assess the safety, PK, and predicted neutralizing activity of AZD3152 compared with EVUSHELD for pre-exposure prophylaxis of COVID-19.
Primary Outcome
Primary: (Main Cohort) Occurrence of AEs collected through approximately 90 days after each IMP administration; SAEs, MAAEs, and AESIs collected through Day 451
Interventions
- BIOLOGICAL AZD5156 (Parent study Sentinel Safety Cohort)
- BIOLOGICAL Placebo (Parent study Sentinel Safety Cohort)
- BIOLOGICAL EVUSHELD™ (Parent study Main Cohort)
- BIOLOGICAL AZD3152 (Parent study Main Cohort)
- BIOLOGICAL Placebo (Parent study Main Cohort)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,882 participants |
| Start Date | 2022-12-16 |
| Est. Completion | 2025-02-11 |
| Phase | Phase 2 |
What the finished NCT05648110 record still lists
NCT05648110 is an interventional study that assigns participants to a tested intervention. Its 3,882 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (2819% higher).
The record links to 0 conditions, and to 5 interventions - of which AZD5156 (Parent study Sentinel Safety Cohort) is the first listed.
NCT05648110 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05648110 about?
NCT05648110 is a clinical study titled "Parent Study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA Sub-study)". AZD3152, a single mAb, is being developed to have broad neutralizing activity across known SARS-CoV-2 variants of concern for pre-exposure prophylaxis of COVID-19. The aim of the Phase I/III study (Parent Study) will be to evaluate the safety, efficacy and neutralizing activity of AZD3152 compared ...
What is the current status of trial NCT05648110?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 3,882 participants. The study started on 2022-12-16. Estimated completion is 2025-02-11.
What interventions are being tested in trial NCT05648110?
The interventions under investigation include: AZD5156 (Parent study Sentinel Safety Cohort) (BIOLOGICAL), Placebo (Parent study Sentinel Safety Cohort) (BIOLOGICAL), EVUSHELD™ (Parent study Main Cohort) (BIOLOGICAL), AZD3152 (Parent study Main Cohort) (BIOLOGICAL), Placebo (Parent study Main Cohort) (BIOLOGICAL).
Who is sponsoring clinical trial NCT05648110?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05648110's enrollment target sits among peer trials
3,882 6th of 2000 higher than 1,995 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05919342 · 3,904 participants · NA
Screening for earlY Heart Failure Diagnosis and Management in Primary Care or at HOme Using Natriuretic Peptides and echocardiographY "SYMPHONY-HF"
- NCT07087613 · 3,850 participants
Deep Learning Detection of Pulmonary Hypertension and Low Ejection Fraction Via Digital Stethoscope and 3-Lead ECG
- NCT03936335 · 3,930 participants
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
- NCT05879926 · 3,960 participants · Phase 3
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI